Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD5851 |
Synonyms | |
Therapy Description |
AZD5851 comprises T-cells engineered to express a chimeric antigen receptor (CAR) targeting GPC3 and a dominant negative TGF-beta type II receptor, which may inhibit tumor growth (J Immunol (2023) 210 (1_Supplement): 68.17) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD5851 | AZD-5851|AZD 5851|Autologous dnTGF-BRII-armored Anti-GPC3 CAR T-cells | AZD5851 comprises T-cells engineered to express a chimeric antigen receptor (CAR) targeting GPC3 and a dominant negative TGF-beta type II receptor, which may inhibit tumor growth (J Immunol (2023) 210 (1_Supplement): 68.17) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06084884 | Phase Ib/II | AZD5851 | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (ATHENA) | Recruiting | USA | 2 |